- Date: November 28, 2019
Onira Research, a biomedical project from IRB Lleida, has recently been awarded first place in the prestigious EIT Health Medtech Bootcamp. Yet another recognition for this project, which was selected in the 2016 edition of CaixaImpulse Validate as well as the pilot CaixaImpulse Consolidate programme in 2018.
Onira is advancing in the go-to-market strategy of a new technology for the diagnosis and treatment of resistant hypertension, which affects 10-15% of all people suffering from high blood pressure. The Onira team, led by experts in the field of sleep and respiratory medicine, Dr. Manuel Sánchez and Dr. Ferran Barbé, both researchers at CIBERES, had previously shown that CPAP (Continuous Positive Air Pressure), a commonly used treatment for sleep apnea, lowers blood pressure to safe levels in up to 70% of these patients.
With the support of CaixaImpulse, they have developed a diagnostic kit to ascertain which patients will benefit from this treatment, to deliver a more personalised care. While working on pushing their project towards commercialization, the team has grown and now includes hypertension specialist Dr. Gerard Torres, CEO Pablo Campos, and advisors Carlos Álvarez and Ramón Tisaire.
This EIT Health Medtech Bootcamp competition ran over several months. During the final phase, start-ups pitched their ideas in front of investors and specialists in a tour around Europe. After 50 pitches and many kilometers, Onira Research was proclaimed winner in Lisbon, by an international jury coming from the event Web Summit 2019.
As part of their prize, Onira will present their project at the EIT Health Summit in Paris in December, one of the most important gatherings for investors and other stakeholders in the European health innovation ecosystem.
More programme highlights
May 19, 2020
Six projects have been selected to receive a total of €1.8 million in the CaixaImpulse COVID-19 Express Call to fast-track their progress towards the market and society.
March 18, 2020
These projects, which offer solutions to unmet biomedical needs, will each receive up to €300,000 to bring their asset to an investment-ready stage.
February 28, 2020
On the occasion of World Rare Disease Day, we spoke with Rubén Artero and Beatriz Llamusí, who form part of the former CaixaImpulse 2017 project MBNL.